You may be right about that - you certainly are about how the first PR was received - although Adam and the market helped that along. It's rather amazing to me that the Mayo Clinic measles virus patient has received so much national coverage (and I can't deny that is very interesting), but that all you could hear were crickets when this sarcoma lung case pr'd.
From a pr, marketing, advertising perspective only - I think a separate PR addressing each area of focus (breast to brain metastasis, colon, melanoma, and "other") would be a unique way of presenting the information - with each given it's due on its own - as opposed to lumping it all together into one. I think if they did it like this, the interest would start to really grow - both as a result of the novel approach this type of public relations campaign would be - as well as for the amazing results we all hope direct is capable of. People would start to sit up and pay attention - and wonder what case will next be revealed. I know I am wondering what the next case will be. And didn't Les in his email imply something like that? I can't remember and I don't have time to go hunt for the post.
I don't know if the company has to give exact data (percentages of necrosis, etc.) by ASCO - or ever - or if they can wait and give that more detailed information at ASCO.
I think if I were an oncologist, and I'd read these multiple pr's (that didn't have the exact details), I would definitely stop by the monster NWBO booth at ASCO to inquire about those exact percentages.
I understand that wouldn't be the way most bio company's pr's are done - but NWBO doesn't do things in the usual way (speaking out when AF puts out a hit piece, etc.). And they have a product that appears to perhaps be "killing" all types of cancer - not just one. Which is also different.
Anyhow, it's more a marketing curiosity now to me as to how they plan to address this - I think either way, it'll be an interesting two weeks.
Market Data 
Markets 
AI
